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AIMS AND SCOPE OF THE VDR EXPERT 
CENTERS INITIATIVE
Our understanding of the vitamin D recep-
tor (VDR) and the eff ects of VDR activation 
has changed dramatically in recent years, with 
the publication of several new studies looking 
at selective VDR activation and eff ects on the 
cardio-renal syndrome (CRS).1 Th ese advances 
have the potential to change the perspective 
of VDR activation beyond its role in mineral 
metabolism. Pleiotropic vitamin D eff ects have 
come into the focus of interest. Th e VDR Expert 
Centers are an independent scientifi c organiza-
tion comprising a group of European academic 
medical centers aligned to enhance the scien-
tifi c understanding of the VDR. Th e group is 
focused on increasing research collaborations, 
medical education, and the dissemination of 
knowledge in the fi eld of VDR activation. A fel-
lows’ educational program runs alongside and 
is intended to increase interest and build skills 
in clinicians and researchers entering the fi eld. 
Additionally, the VDR Expert Centers collabo-
rate on research and other projects concerned 
with the VDR, including an annual Grand 
Rounds symposium, which brings together 
experts in the fi eld to share the latest infor-
mation in this area. Th is supplement serves 
as a review of the data that were discussed at 
the inaugural Grand Rounds symposium in 
Amsterdam in September 2010.
A CALL FOR HOMOGENOUS NOMENCLATURE
Alongside the scientific advancements sur-
rounding the VDR, at both preclinical and 
clinical levels, it is clear that the nomenclature 
for vitamin D and VDR activators has become 
more complex, though not necessarily consist-
ent. Here, the authors of this supplement have 
agreed to standardize terms between the articles, 
so that it is clear from the outset to what mol-
ecule each author refers. For clarity in interpret-
ing the results of each investigation, compounds 
are distinguished precisely; they have diff erent 
structures, some are inactive, some activate the 
VDR, and not all are detectable in the assays 
performed to obtain a ‘vitamin D’ level in our 
patients. Table 1 provides a summary of the vita-
min D and VDR activator nomenclature used in 
the articles in this supplement, the fi nal column 
to the right containing the preferred shorthand 
term used here. Th roughout, this allows for a 
comparison of each study and a recognition that 
each compound may act diff erently on the same 
receptor.
FIGHTING VITAMIN D DEFICIENCY: 
WHAT ARE APPROPRIATE VITAMIN D LEVELS? 
Another important issue regarding consistency 
in the fi eld of vitamin D is the recommended 
target level of 25-hydroxyvitamin D (25D), 
both in the general population and in chronic 
kidney disease (CKD) patients. Th e debate con-
tinues about how much 25D is enough or too 
much. Th ere is a lack of agreement between 
various guidelines and experts in what clinical 
levels of 25D are required and also how much 
has to be taken as supplements to achieve this. 
Recommendations and guidelines for optimum 
vitamin D levels are currently based on epide-
miological and observational data and rand-
omized controlled trials related to vitamin D 
intake and health outcomes are few. Vitamin D 
defi ciency in the general population with nor-
mal renal function causes secondary hyperpar-
athyroidism (SHPT), bone loss, and is strongly 
associated with a higher risk for hypertension, 
proteinuria, cardiovascular (CV) lesions, and 
higher rates of CV mortality.2 Th is exemplifi es 
the broad role that vitamin D has in several bio-
logical processes for the maintenance of gen-
eral health. Nevertheless, various professional 
groups currently recommend diff erent levels of 
25D for optimal effi  cacy. For example, pulmon-
ologists interested in cystic fi brosis, a condition 
where vitamin D defi ciency is common, recom-
mended maintaining 25D levels above 35 ng/ml 
(87.5 nmol/l) for individuals with cystic fi brosis 
to avoid SHPT and bone loss.3 Th e Institute of 
Medicine of the National Academies (IOM) 
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recently published guidelines on vitamin D 
supplementation for the general population, 
which were much lower.4 The IOM stated 
that, based on available data, almost all indi-
viduals have suffi  cient 25D when their blood 
levels are >20 ng/ml (50 nmol/l) and that there 
is little additional benefi t above 30 ng/ml (75 
nmol/l). In these guidelines, bone health was 
selected as the indicator to serve as the basis of 
the Dietary Reference Intake (DRIs) for Ca and 
vitamin D. Th ey found compelling evidence 
supporting the role for Ca and vitamin D in 
skeletal health. On the other hand, the report 
was inconclusive as to whether supplementing 
with native vitamin D or Ca is of benefi t in non-
skeletal outcomes. Th ese non-skeletal outcomes 
are exactly what make us question whether the 
recent IOM recommendations are justifi ed. 
Limiting the appropriate vitamin D level to 20 
ng/ml of 25D has initiated a vigorous scientifi c 
debate in the international literature. Currently, 
the VDR Expert Centers group, in line with the 
previous 2003 K/DOQI guidelines5 and the 
recent Spanish recommendations for CKD–
mineral and bone disorder (CKD–MBD) have 
decided to suggest a 25D target level of >30 
ng/ml.6 Consequently, this VDR Expert Cent-
ers group essentially agrees that 25D levels of 
Table 1.  Vitamin D and VDR activator nomenclature
Class of 
compounds Description Name Molecule Structure
Standardized 
nomenclature
Vitamin D Dietary or native vitamin D Cholecalciferol
Ergocalciferol
Vitamin D3
Vitamin D2
Native vitamin D
Product of the first hydroxylation 
of vitamin D in the liver
Calcidiol 25-hydroxyvitamin D 25D
Active vitamin D Product of the second 
hydroxylation of vitamin D in the 
kidneys. Binds the VDR directly
Calcitriol 1,25-dihydroxyvitamin D3 1,25D
A synthetic analog of calcitriol, 
converted to calcitriol in the liver 
before binding the VDR
Alfacalcidol 1α-hydroxyvitamin D3 1-alpha
Selective VDR 
activator
Acts as a synthetic agonist to 
the VDR, but is not converted 
to calcitriol before binding. 
Selectively activates downstream 
pathways (i.e., less effect on Ca 
and P absorption in the gut)
Paricalcitol 19-NOR-1α 
dihydroxyvitamin D2
Selective VDR 
activator
Maxacalcitol 22-oxa-1,25-
dihydroxyvitamin D3
Selective VDR 
activator
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20 ng/ml are too low for the well-being of CKD 
patients, and that levels of >30 ng/ml would 
maximize benefi t.
The debate on optimum 25D levels are 
discussed in detail by the authors in this sup-
plement. In their article, Pilz et al. refl ect that 
most CKD patients are 25D defi cient, with lev-
els below the target of 30 ng/ml; the authors 
discuss the subsequent negative consequences 
for an increased risk of CV diseases and CV 
mortality. Hence, their group recommend 
testing for 25D levels and treating defi ciency, 
according to current KDIGO guidelines, and 
aim, in general, for a suffi  cient vitamin D status 
with 25D levels of 30 ng/ml, the ideal target 
level according to many sources.5 – 9
VITAMIN D: WHEN IS ENOUGH TOO MUCH? 
However, Adriana Dusso discusses all the plausi-
ble advantages and problems of further increas-
ing vitamin D levels, acknowledging that levels of 
25D above 50 ng/ml may be detrimental to health 
and survival.10 In any case, increases in plasma Ca 
and/or P, and probably increases in calciuria, may 
represent indirect evidence of undesirable high 
levels of 25D. Cozzolino and Bover address the 
issues of vitamin D levels and eff ect on mineral 
metabolism and bone, as well as their relation to 
the vasculature. Th e authors agree that the evi-
dence points to a narrow range of 25D levels at 
which vascular function is optimized.11 Th e VDR 
Expert Centers group acknowledges the fact that 
vitamin D is a potent hormone for which the risk 
of potential side eff ects correlates with high stor-
age levels. However, we feel that any upper level of 
recommendation is even less well defi ned than the 
lower 25D level of >30 ng/ml. Exploring the opti-
mal range of vitamin D levels in CKD patients, 
avoiding undertreatment as well as oversupple-
mentation, is one of the main future research 
topics of the VDR Expert Centers group.
VITAMIN D AND CLOSELY RELATED ISSUES 
OF CKD–MBD
Th e review by Brandenburg et al. highlights the 
substantial developments that have taken place 
in the VDR arena in the past decade. Specifi -
cally, actions of the VDR in the heart have been 
explored, and the importance of vascular cal-
cifi cations in CKD as the cause of signifi cant 
morbidity and mortality has been documented. 
Th e authors have selected what they believe are 
landmark publications that have improved our 
understanding of the mechanisms involved in 
the development of what they term ‘vascular 
calcifi cations in uremia,’ as well as the clinical 
approaches we now have to improve vascular 
health in CKD. Th ey touch on an article that 
introduced Klotho and FGF23 into the world 
of nephrology, and in their review Vervloet 
and Larsson explore in depth the fascinating 
discovery and mechanisms of action of these 
compounds. Importantly, FGF23 is a potent 
negative regulator of circulating P and 1,25D, 
so it will be interesting to see how its clinical 
implications in CKD as a biomarker and/or 
therapeutic target develop.
PERSPECTIVES
Looking to the future, randomized, controlled 
trials for optimizing the treatment of CKD–MBD 
are still needed, and more work is required to 
defi ne optimal target levels of Ca, P, PTH and 
vitamin D—as well as the new players, FGF23 
and Klotho—in this population. Th ere is also the 
need to defi ne the potential diff erences between 
VDR activation with the administration of native, 
active, or selective forms of VDR activators. What 
is clear from all the articles in this supplement 
is that lack of VDR activation in CKD patients 
is a signifi cant problem that is associated with 
accelerated renal and CV disease progression 
and death.12,13 Th e safe correction of this defi -
ciency without disturbing the Ca and P balance is 
becoming a high priority for nephrologists.
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